CEO Executive AssistantThe pharma CEO guide to commercial operations management addresses one of the most complex and highest-stakes operational challenges in any industry. Commercial operations in pharma are not simply sales management. They encompass the full architecture of how a medicine reaches patients: from market access negotiations with payers, to the information flow between field teams and healthcare providers, to the regulatory discipline that protects promotional integrity, to the analytics infrastructure that tells you whether your commercial model is working.
CEOs who treat commercial operations as a sales leadership problem consistently underinvest in the systems that actually determine commercial performance. This guide is for pharma CEOs who want to build commercial operations that are rigorous, scalable, and aligned with both the business and the science.
The Commercial Operations Mandate
Commercial operations in the pharmaceutical industry operate under constraints that have no equivalent in most other sectors. Every customer-facing interaction is governed by regulatory standards. Every claim made by a sales representative must be supported by approved labeling and cleared through medical, legal, and regulatory review. Every market access strategy must navigate an increasingly sophisticated and resistant payer environment. Every data point generated by commercial activities is subject to healthcare provider privacy regulations.
Within these constraints, commercial operations must also drive revenue growth, protect market share, support launch execution, and demonstrate the value of investment to a board and investor base that expects clear return attribution. According to McKinsey research on pharmaceutical commercial models, companies that build integrated commercial operations outperform those with fragmented, function-by-function approaches by a significant margin in launch performance and long-term market share retention.
The CEO’s commercial operations mandate is to build the systems, governance, and talent architecture that enable commercial excellence at scale, without getting pulled into the tactical execution that belongs to the commercial leadership team.
Structuring Sales Force Effectiveness
Sales force effectiveness (SFE) is both a function and a discipline within pharma commercial operations. As a function, it encompasses territory design, call planning, incentive compensation, training, and performance analytics. As a discipline, it is the continuous process of ensuring that every sales investment is optimized to generate maximum appropriate patient impact.
Territory design is the foundation of SFE and is frequently undervalued by commercial leaders who focus on individual rep performance rather than structural effectiveness. Territory design should be rebuilt or validated whenever a product launches, when a significant competitive entry changes market dynamics, or when data shows systematic geographic performance disparities that cannot be explained by rep capability.
Incentive compensation design is where SFE decisions have the most direct impact on commercial culture. Pharma incentive compensation systems that are overly complex, that reward activity rather than outcomes, or that create misalignment between what reps optimize for and what the business needs consistently produce underperformance. Build incentive compensation plans that are simple enough for every rep to understand their own trajectory, aligned with formulary and market access outcomes rather than just prescription volume, and reviewed annually against both business results and competitive benchmarks.
Call planning and customer segmentation should be driven by data, not by field manager intuition. Build a segmentation model that integrates prescribing data, patient population density, formulary status, and physician accessibility into a tiered targeting framework. This model should be maintained by a dedicated analytics function and updated on a quarterly basis. Reps who receive data-driven call plans consistently outperform reps who self-select their targeting.
Sales force size and structure decisions are strategic choices that the CEO must own. Determining whether to field a dedicated sales force, a co-promotion partnership, a hybrid model, or a contract sales organization requires integrating commercial strategy, financial modeling, and patient access considerations. Build a formal sales force sizing model that is reviewed at each annual planning cycle and whenever launch or lifecycle management decisions require it.
Managing Market Access and Payer Operations
Market access is the most consequential commercial operations domain for most pharma companies. Without favorable formulary positions, prior authorization criteria that reflect clinical reality, and step therapy requirements that do not prevent appropriate patients from accessing your medicine, field force effectiveness is constrained regardless of quality.
Build a dedicated market access function with clear accountability for national account relationships with pharmacy benefit managers (PBMs), regional payer negotiations, government payer strategy (Medicare, Medicaid), and integrated delivery network (IDN) engagement. The head of market access should sit at the commercial leadership table, not report to the sales leader.
Payer value proposition development is where commercial operations and medical affairs intersect. The evidence package that supports formulary positioning, prior authorization criteria design, and step therapy policy must integrate clinical trial data, real-world evidence, health economic modeling, and comparative effectiveness data. Build a cross-functional process that aligns medical affairs, market access, and HEOR teams around payer value dossier development at least eighteen months before a product launch.
Formulary tracking operations should provide real-time visibility into coverage status across all major payers, broken down by channel (commercial, Medicare Part D, Medicaid, VA/DoD). This data should be integrated into field force call planning so that reps are prioritizing prescribers whose patients have coverage rather than spending time in markets where access barriers make conversion unlikely regardless of engagement quality.
Patient services operations, including copay assistance programs, patient assistance programs, and hub services, are a critical component of market access that is often managed separately from core market access operations. Build an integrated patient services strategy that addresses the full continuum from prescription to patient access, with metrics that track abandonment rates at each step in the dispensing process.
Coordinating Medical, Legal, and Regulatory Review
The medical, legal, and regulatory (MLR) review process is one of the most important and most commonly dysfunctional governance systems in pharma commercial operations. When MLR works well, it protects the organization from regulatory risk while enabling timely approval of promotional materials. When it does not work well, it creates bottlenecks that stall commercial campaigns, frustrate commercial teams, and generate workarounds that introduce greater risk.
The CEO should set the expectation that MLR is an enabling function, not simply a compliance function. The standard for a well-functioning MLR process is not “everything gets reviewed” but “everything gets reviewed appropriately and efficiently, with clear timelines and transparent decision criteria.”
Build a structured MLR process with defined submission standards, review timelines by material type, committee composition requirements, and an escalation protocol for contested decisions. Submission standards specify what must be included in an MLR package before it enters the queue. Review timelines establish maximum turnaround commitments for each material type, with standard reviews completed in ten to fifteen business days and expedited reviews available for time-sensitive materials within five business days. Escalation protocols define how disagreements between reviewers are resolved without creating indefinite delays.
MLR committee composition matters. Medical reviewers bring clinical accuracy and labeling compliance expertise. Legal reviewers address promotional law, intellectual property, and litigation risk. Regulatory reviewers ensure alignment with approved labeling and regulatory guidance. The chair of the MLR committee should rotate or be shared across functions, with no single function effectively controlling the process.
Track MLR cycle time and first-pass approval rates as operational metrics. Long cycle times and low first-pass approval rates indicate systemic problems, whether in submission quality, reviewer calibration, or committee composition. Build a quarterly MLR performance review into commercial operations governance and treat persistent MLR dysfunction as a leadership issue, not an administrative one.
Building Commercial Analytics Infrastructure
Commercial analytics is the intelligence system of pharma commercial operations. Without robust analytics infrastructure, commercial decisions are made on intuition, lagging data, and incomplete information. With strong analytics capabilities, commercial operations can identify market opportunities earlier, allocate resources more precisely, and detect performance problems before they become material.
The commercial analytics infrastructure for a mid-to-large pharma company should include: a data warehouse that integrates third-party data sources (IQVIA, Symphony, claims data), customer relationship management data, market access data, and financial data; a suite of standard reporting dashboards for commercial leadership, field management, and market access; a modeling capability for territory optimization, incentive compensation modeling, and market simulation; and an advanced analytics capability for customer segmentation, predictive targeting, and real-world evidence generation.
Data governance is a prerequisite for analytics effectiveness. Establish clear data ownership, validation standards, and access controls before building analytics products. Poor data governance produces analytics outputs that are disputed, distrusted, and ultimately ignored. Designate a commercial data governance committee with representation from commercial analytics, IT, compliance, and privacy to own these standards.
Field force reporting should provide field managers and commercial leaders with daily, weekly, and monthly views of performance against plan, covering call activity, reach and frequency metrics, prescription performance by territory and account, and market access status. These reports should be accessible through mobile tools that field managers can use during field rides and coaching sessions.
Executive commercial dashboards should provide the CEO and commercial leadership with a monthly view of brand performance against plan, market share trends, payer access status, pipeline performance by geography, and leading indicators of risk or opportunity. Dashboards that surface leading indicators rather than only lagging results give commercial leaders time to intervene before problems become material.
Managing Launch Readiness Reviews
Product launches are the highest-stakes moments in pharma commercial operations. Launch readiness is not a point-in-time assessment; it is an ongoing operational discipline that spans eighteen to twenty-four months before launch through the first year of commercial activity.
Build a formal launch readiness review (LRR) process that operates on a quarterly cadence in the eighteen months before launch and transitions to a monthly cadence in the final six months. The LRR should evaluate readiness across all commercial functions: sales force training, market access contracting, marketing materials MLR status, patient services program activation, medical affairs engagement, trade and distribution channel setup, and medical education programming.
Use a launch readiness scorecard that rates each functional domain on a standard scale (red/yellow/green or a numerical scoring system) and aggregates to an overall launch readiness score. The scorecard should be reviewed by commercial leadership at each LRR and by the CEO and executive committee at quarterly intervals. Any domain in red status should have an explicit remediation plan with a defined owner and timeline.
Launch performance tracking begins at day one of commercial availability. Build a launch performance dashboard that tracks weekly prescription data against forecast, payer coverage status by plan and channel, field force activity metrics, patient services enrollment, and competitive response. Review this dashboard weekly with commercial leadership in the first year of launch and maintain a standing launch performance review meeting with escalation protocols for variances that exceed threshold.
For the broader context of how regulatory affairs connects to commercial launch readiness, the pharma regulatory affairs ops framework provides the upstream operational discipline that commercial launch depends on.
Aligning Commercial and Medical Affairs
The relationship between commercial and medical affairs is one of the most important and most frequently mismanaged structural relationships in a pharma company. Commercial affairs drives revenue generation; medical affairs is responsible for scientific exchange and evidence generation. When these functions are not aligned, both suffer: commercial teams lack the medical credibility they need with sophisticated healthcare systems, and medical affairs lacks the organizational support to execute evidence programs that address real market needs.
Build formal alignment mechanisms between commercial and medical affairs at both the strategic and operational levels. At the strategic level, commercial and medical leadership should co-develop the integrated brand strategy, ensuring that evidence generation priorities, KOL engagement strategies, and disease state education programs are aligned with the commercial value proposition and market access strategy.
At the operational level, build cross-functional processes for: pre-launch medical education planning, advisory board coordination (ensuring commercial insights inform advisory board agendas without compromising scientific integrity), publication planning that addresses commercially relevant data gaps, and real-world evidence generation programs that generate the comparative effectiveness data payers require.
Establish clear boundaries and compliance guardrails that govern commercial-medical interactions. The independence of medical affairs from commercial influence is both a regulatory requirement and a credibility asset. Build a clear policy framework that defines permissible interactions, required approvals for joint activities, and documentation standards for all commercial-medical coordination. These boundaries should be enforced actively, not simply documented in a policy that nobody reads.
The pharma CEO ops guide provides the broader operational context within which commercial and medical affairs alignment sits.
CEO Governance of Commercial Operations
The CEO’s role in commercial operations is to set direction, establish governance, build the commercial leadership team, and hold that team accountable for performance, not to run commercial operations personally.
Build a commercial operations governance structure that includes a monthly commercial leadership review, a quarterly brand strategy review, and an annual commercial planning process with formal CEO engagement at key milestones. The monthly commercial leadership review should focus on performance against plan, resource deployment decisions, and cross-functional issue resolution. The quarterly brand strategy review should address market trends, competitive developments, and strategic pivots. The annual planning process should produce a commercial plan that the CEO formally approves, with clear financial and operational commitments tied to resource allocation decisions.
The commercial leadership team is the CEO’s most critical staffing decision in a commercial-stage pharma company. The chief commercial officer or head of commercial must combine strategic insight with operational rigor, market access expertise with field force credibility, and analytical discipline with the interpersonal effectiveness to lead large field organizations. Invest in this role. The cost of a weak commercial leadership appointment is measured in lost market share and missed launch performance.
Conclusion
Pharma commercial operations management is a discipline that rewards CEOs who treat it as a system, not a collection of functional silos. Sales force effectiveness, market access, MLR governance, analytics infrastructure, launch readiness, and commercial-medical alignment are interconnected operations that amplify each other when they work well and undermine each other when they do not.
The most effective pharma CEOs set clear commercial strategy, build strong commercial leadership teams, establish the governance processes that keep commercial operations disciplined and aligned, and maintain the rigor in commercial analytics that allows them to distinguish signal from noise in performance data. They do not run commercial operations themselves, but they understand them well enough to ask the right questions and recognize when the answers are not sufficient.
Building commercial operations at this level of rigor is not optional for companies that want to sustain competitive performance across product generations and market cycles. It is the operational foundation on which pharmaceutical commercial success is built.
Related Reading
For further context, explore Pharma CEO Guide to Business Development Operations and Pharma CEO Guide to Business Operations Management.